Emerging data suggest this peptide, a dual activator targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , could represent a promising advancement for weight loss . Early clinical investigations have indicated considerable losses in visceral tissue, potentially exceeding existing weight-loss treatments. Nevertheless ,